Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
18
NCT02626507
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2016
Completion: Mar 15, 2022